INS and type 1 diabetes mellitus: Forthose with recent-onset stage 3 T1D, a 14-day full-dose intervention induced less AUCC-peptide decline, lower insulin requirement, and better glycemic control thanconventional treatment in a multicenter randomized trial (n = 516) after one year(56).